Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse eventsCompany expects to complete enrollment of ...

Bill Russell and Jim Rieker are survivors. Both diagnosed with bladder cancer, the men have made it their mission to help others with the disease through the Bladder Cancer Advocacy Network, the ...

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer ...

Staying fit and active has long been associated with better heart and overall health. It might also improve the chances of ...

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small ...

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...

Overall survival appears no worse for patients with organ-confined limited-stage small cell bladder cancer receiving multimodal organ-preserving treatment. For patients with limited-stage small-cell ...

RAANANA, Israel (Reuters) - Israel's UroGen Pharma plans to begin a mid-stage trial of its treatment for bladder cancer patients in August, after positive interim results last month from an advanced ...

Detailed price information for Theralase Technologies Inc (TLT-X) from The Globe and Mail including charting and trades.

Categorizing patients with cancer by their disease stage can be an important tool when conducting administrative claims-based studies. As claims databases frequently do not capture this information, ...